EPROSARTAN

Bezeichnung:EPROSARTAN

CAS-Nr133040-01-4

Englisch Name:EPROSARTAN

CBNumberCB0135346

SummenformelC23H24N2O4S

Molgewicht424.51

MOL-Datei133040-01-4.mol

EPROSARTAN physikalisch-chemischer Eigenschaften

Schmelzpunkt	250-253°C
storage temp.	Sealed in dry,2-8°C
Löslichkeit	Dichloromethane (Slightly), Methanol (Slightly)
Aggregatzustand	Solid
Farbe	Pale Yellow to Light Yellow
CAS Datenbank	133040-01-4

Sicherheit

Giftige Stoffe Daten

133040-01-4(Hazardous Substances Data)

Gefahreninformationscode (GHS)

EPROSARTAN Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Teveten was launched in Germany for the treatment of hypertension. There are several ways in which it has been prepared, the shortest of which is four steps; beginning with displacement of 2-butyl-4-chloroimidazole-5-carboxaldehyde with methyl 4-(bromomethyl)benzoate. Teveten is an angiotensin Ⅱ antagonist selective for the AT, subtype receptor. It is a potent, highly selective, competitve antagonist with no agonist activity. Duration of action is similar to Enalapril (greater than 12 hr) but Teveten had a faster onset. While it is orally active, it rapidly dissociates from the receptor. This is contrary to its prolonged duration of action, which presumably results from slow removal from compartments within tissue, cells or matrix around the AT, receptor. It is not bound by BSA.
Chemische Eigenschaften
Light-Yellow Solid
Originator
SmithKline Beecham (UK)
Verwenden
Prototype of the imidazoleacrylic acid angiotensin II receptor antagonists. Antihypertensive
Verwenden
Eprosartan is a prototype of the imidazoleacrylic acid angiotensin II receptor antagonists. Eprosartan is an antihypertensive.
Verwenden
Eprosartan (E590100) impurity.
Definition
ChEBI: A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.
Trademarks
Teveten
Clinical Use
Angiotensin-II antagonist
Hypertension
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia hypotension and renal impairment with ACE inhibitors and aliskiren.
Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
Epoetin: increased risk of hyperkalaemia; antagonism of hypotensive effect.
Lithium: reduced excretion, possibility of enhanced lithium toxicity.
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.
Stoffwechsel
Following oral and intravenous dosing with [14C] eprosartan in human subjects, eprosartan was the only drug-related compound found in the plasma and faeces. In the urine, approximately 20% of the radioactivity excreted was an acyl glucuronide of eprosartan with the remaining 80% being unchanged eprosartan
Eprosartan is eliminated by both biliary and renal excretion. Following intravenous [14C] eprosartan, about 61% of radioactivity is recovered in the faeces and about 37% in the urine. Following an oral dose of [14C] eprosartan, about 90% of radioactivity is recovered in the faeces and about 7% in the urine.

EPROSARTAN Upstream-Materialien And Downstream Produkte

EPROSARTAN Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

133040-01-4, EPROSARTAN Verwandte Suche:

Send Inquriy